Skip to main content
. 2017 Apr 29;8(32):52584–52593. doi: 10.18632/oncotarget.17526

Figure 3. HER3 siRNA potentiates the effect of gefitinib.

Figure 3

(A) Comparative growth inhibition rates of MKN45, MKN45-HER3-cs and MKN45-HER3.3 cells exposed to gefitinib. Control siRNA- and HER3.3-transfected MKN45 cells (2 × 103 cells/well) were grown in DMEM supplemented with 10% FBS in 96-well plates for 48 h and treated with various concentrations of gefitinib for 48 h. HER3.3 potentiates the effect of gefitinib on MKN45 cell growth, as determined by an MTT assay. The results represent the means ± SDs of three independent experiments. (B) Structure of gefitinib. Gefitinib treatment of MKN45 cells significantly induces HER3 (C) and HER2 (D) mRNA expression, and this induction is prevented by HER3.3 (C). Induction of HER2 expression by gefitinib is not prevented by HER3.3 (D). *P < 0.05 compared with control cells.